Combination drug
AssigneeChugai Seiyaku Kabushiki Kaisha
InventorsHiroshi SAKAMOTO, Toshiyuki TSUKAGUCHI
Life of this patent
Estimating the term…
Abstract
The present invention relates to a drug that is for treating or preventing cancer, that is effective in the treatment of cancer, and that comprises a combination of an ALK inhibitor and a VEGF inhibitor. The present invention also relates to a method for treating or preventing cancer and a method for inhibiting tumor growth.
Claims51
A medicament for treating or preventing a cancer, the medicament being produced by combining an ALK inhibitor and a VEGF inhibitor.
A medicament for treating or preventing a cancer, the medicament being used with a VEGF inhibitor, comprising an ALK inhibitor as an active ingredient.
A medicament for treating or preventing a cancer, the medicament being used with an ALK inhibitor, comprising a VEGF inhibitor as an active ingredient.
A method of treating or preventing a cancer comprising:
- administering, in combination, an effective amount of ALK inhibitor and an effective amount of VEGF inhibitor to a subject.
A method of enhancing a therapeutic effect of an ALK inhibitor on a cancer, the method comprising:
- administering an effective amount of VEGF inhibitor to a subject.
A method of extending a tumor progression-free survival comprising:
- administering, in combination, an effective amount of ALK inhibitor and an effective amount of VEGF inhibitor to a subject.
A method of suppressing growth of a tumor comprising:
- administering, in combination, an effective amount of ALK inhibitor and an effective amount of VEGF inhibitor to a subject.
A product comprising (1) a formulated agent containing a VEGF inhibitor, (2) a container, and (3) an instruction leaflet or label indicating that the VEGF inhibitor and at least one ALK inhibitor are administered in combination to a subject to treat a cancer.
A product comprising (1) a formulated agent containing an ALK inhibitor, (2) a container, and (3) an instruction leaflet or label indicating that the ALK inhibitor and at least one VEGF inhibitor are administered in combination to a subject to treat a cancer.
Dependencies are inferred from the claim text.